Figure 1.

Prophylactic effect of aluminium-based adjuvants FH-001 and Al-001. (A) Transmission electron microscopy of FH-001 and Al-001. Scale bar, 100 nm. (B) Survival rate and weight change of BALB/c mice after intramuscular administration of FH-001 and lethal challenge by B/Florida/4/2006 (Short as “FL/2006”). The BALB/c mice that were intramuscularly administered with physiological saline were challenged by FL/2006 and used as the negative control (NC) group, n = 4 mice per group. (C) Survival rate and weight change of BALB/c mice after intranasal administration of FH-001 and lethal challenge by FL/2006. The BALB/c mice that were intranasally administered with physiological saline were challenged by FL/2006 and used as NC group, n = 4 mice per group. (D-E) Survival rate and weight change of BALB/c mice after administration of FH-001 via different routes and lethal challenge by FL/2006, n = 4 mice per group. (F) Survival rate of 1- to 200-fold diluted FH-001 treated BALB/c mice after a lethal challenge of FL/2006. The BALB/c mice that were intranasally administered with physiological saline were challenged by FL/2006 and used as NC group. Five BALB/c mice were used in each FH-001 treated group, four mice were used in NC group. (G) Fourteen days weight change of 1- to 200-fold diluted FH-001 treated mice after FL/2006 challenge. (H–I) The survival rate of 10-fold diluted FH-001 treated mice (treated for different durations) after the challenge of FL/2006 (n = 4 mice per group). (J) Viral titer of FL/2006 in lungs from two groups (FH-001-treated mice or physiological saline-treated mice) at different time points after the challenge of the FL/2006. (K–L) Haematoxylin-eosin staining of lung tissues from FH-001 or 0.9% saline-treated mice after the challenge of FL/2006.